Niethammer Thomas R, Valentin Siegfried, Ficklscherer Andreas, Gülecyüz Mehmet F, Pietschmann Matthias F, Müller Peter E
Int Orthop. 2015 Aug;39(8):1615-22. doi: 10.1007/s00264-015-2792-9. Epub 2015 May 7.
Third generation autologous chondrocyte implantation (ACI) is an established treatment for full thickness cartilage defects in the knee joint. However, little is known about cases when revision surgery is needed. The aim of the present study is to investigate the complication rates and the main reasons for revision surgery after third generation autologous chondrocyte implantation in the knee joint. It is of particular interest to examine in which cases revision surgery is needed and in which cases a "wait and see" strategy should be used.
A total of 143 consecutive patients with 171 cartilage defects were included in this study with a minimum follow-up of two years. All defects were treated with third generation ACI (NOVACART®3D). Clinical evaluation was carried out after six months, followed by an annual evaluation using the International Knee Documentation Committee (IKDC) subjective score and the visual analogue scale (VAS) for rest and during activity. Revision surgery was documented.
The revision rate was 23.4 % (n = 36). The following major reasons for revision surgery were found in our study: symptomatic bone marrow edema (8.3 %, n = 3), arthrofibrosis (22.2 %, n = 8) and partial graft cartilage deficiency (47.2 %, n = 17). The following revision surgery was performed: retrograde drilling combined with Iloprost infusion therapy for bone marrow oedema (8.4 %, n = 3), arthroscopic arthrolysis of the suprapatellar recess (22.2 %, n = 8) and microfracturing/antegrade drilling (47.3 %, n = 17). Significant improvements of clinical scores after revision surgery were observed.
Revision surgery after third generation autologous chondrocyte implantation is common and is needed primarily in cases with arthrofibrosis, partial graft cartilage deficiency and symptomatic bone marrow oedema resulting in a significantly better clinical outcome.
第三代自体软骨细胞移植(ACI)是治疗膝关节全层软骨缺损的一种成熟方法。然而,对于需要翻修手术的情况了解甚少。本研究的目的是调查膝关节第三代自体软骨细胞移植术后的并发症发生率及翻修手术的主要原因。特别值得关注的是,研究哪些情况下需要进行翻修手术,哪些情况下应采用“观察等待”策略。
本研究共纳入143例连续患者的171处软骨缺损,最小随访时间为两年。所有缺损均采用第三代ACI(NOVACART®3D)治疗。术后6个月进行临床评估,随后每年使用国际膝关节文献委员会(IKDC)主观评分以及静息和活动时的视觉模拟量表(VAS)进行评估。记录翻修手术情况。
翻修率为23.4%(n = 36)。本研究发现以下主要翻修原因:有症状的骨髓水肿(8.3%,n = 3)、关节纤维化(22.2%,n = 8)和部分移植软骨缺损(47.2%,n = 17)。实施的翻修手术如下:逆行钻孔联合伊洛前列素输注治疗骨髓水肿(8.4%,n = 3)、关节镜下髌上隐窝松解术(22.2%,n = 8)和微骨折/顺行钻孔(47.3%,n = 17)。翻修手术后临床评分有显著改善。
第三代自体软骨细胞移植术后翻修手术很常见,主要适用于关节纤维化、部分移植软骨缺损和有症状的骨髓水肿的情况,可显著改善临床结局。